GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Accordingly, GSK investors ... is not well covered by earnings. That said, even highly profitable companies sometimes might not generate enough cash to pay the dividend, which is why we should ...

NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...

Last year GSK paid out 97% of its profits as dividends to shareholders, suggesting the dividend is not well covered by earnings. That said, even highly profitable companies sometimes might not ...

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has bee ...

Citadel did not immediately respond to a Reuters request for comment. GSK declined comment, saying, “It is our consistent position that we do not comment on individual shareholders." A short ...

Now, GSK is ready to play catch-up after nabbing its own FDA approval. The FDA approved the British drugmaker's Penmenvy vaccine to protect people ages 10 to 25 against meningococcal serogroups A ...

Ben Hargreaves examines the reasons supplied by the survey and why GSK is invested in the answers ... found that patients aged 50 and older are not getting vaccinated where healthcare ...

Feb 15 (Reuters) - The U.S. Food and Drug Administration approved British drugmaker GSK's (GSK.L), opens new ... The company told the agency it would not market the product in the European Union ...

The content of this article is provided for information purposes only and is not intended to be ... further dividend growth mean the yields on GSK’s shares soar above the FTSE 100 average ...